RSU1

Summary

RSU1 (Ras suppressor protein 1, HGNC:10464) is a protein-coding gene on chromosome 10p13, encoding Ras suppressor protein 1 (Q15404). Potentially plays a role in the Ras signal transduction pathway.

This gene encodes a protein that is involved in the Ras signal transduction pathway, growth inhibition, and nerve-growth factor induced differentiation processes, as determined in mouse and human cell line studies. In mouse, the encoded protein was initially isolated based on its ability to inhibit v-Ras transformation. Multiple alternatively spliced transcript variants for this gene have been reported; one of these variants was found only in glioma tumors.

Source: NCBI Gene 6251 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 59 total
• Druggable target: yes
• MANE Select transcript: NM_012425

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10464
Approved symbol	RSU1
Name	Ras suppressor protein 1
Location	10p13
Locus type	gene with protein product
Status	Approved
Aliases	RSP-1, FLJ31034
Ensembl gene	ENSG00000148484
Ensembl biotype	protein_coding
OMIM	179555
Entrez	6251

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000345264, ENST00000377911, ENST00000377921, ENST00000464074, ENST00000602389, ENST00000905311, ENST00000905313, ENST00000905315, ENST00000949333, ENST00000949334

RefSeq mRNA: 2 — MANE Select: NM_012425 NM_012425, NM_152724

CCDS: CCDS31157, CCDS7112

Canonical transcript exons

ENST00000345264 — 9 exons

Exon	Start	End
ENSE00001475576	16590611	16593496
ENSE00001958674	16817315	16817424
ENSE00002280374	16816973	16817084
ENSE00003518722	16754871	16754989
ENSE00003527614	16752539	16752653
ENSE00003527644	16752918	16753000
ENSE00003581063	16782034	16782084
ENSE00003682063	16695023	16695155
ENSE00003684779	16764390	16764510

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 97.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 73.2903 / max 757.6939, expressed in 1824 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108460	68.0740	1821
108461	5.1614	1693
108462	0.0549	22

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	97.84	gold quality
tibial artery	UBERON:0007610	97.84	gold quality
right coronary artery	UBERON:0001625	97.77	gold quality
aorta	UBERON:0000947	97.58	gold quality
left coronary artery	UBERON:0001626	97.40	gold quality
descending thoracic aorta	UBERON:0002345	97.40	gold quality
thoracic aorta	UBERON:0001515	97.27	gold quality
ascending aorta	UBERON:0001496	97.22	gold quality
coronary artery	UBERON:0001621	97.21	gold quality
blood vessel layer	UBERON:0004797	97.13	gold quality
calcaneal tendon	UBERON:0003701	96.93	gold quality
monocyte	CL:0000576	96.89	gold quality
mononuclear cell	CL:0000842	96.75	gold quality
leukocyte	CL:0000738	96.50	gold quality
saphenous vein	UBERON:0007318	96.33	gold quality
stromal cell of endometrium	CL:0002255	95.95	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.71	gold quality
smooth muscle tissue	UBERON:0001135	95.63	gold quality
rectum	UBERON:0001052	95.61	gold quality
adipose tissue	UBERON:0001013	95.42	gold quality
connective tissue	UBERON:0002384	95.22	gold quality
body of uterus	UBERON:0009853	95.20	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.12	gold quality
lower esophagus	UBERON:0013473	95.09	gold quality
peritoneum	UBERON:0002358	95.02	gold quality
omental fat pad	UBERON:0010414	95.02	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.00	gold quality
urethra	UBERON:0000057	94.99	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.90	gold quality
myometrium	UBERON:0001296	94.78	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-GEOD-75367	yes	2150.25
E-HCAD-4	yes	37.48
E-CURD-112	yes	35.83
E-HCAD-6	yes	22.93
E-CURD-122	yes	20.78
E-HCAD-10	yes	16.65
E-MTAB-9067	yes	12.85
E-GEOD-83139	yes	7.25
E-HCAD-1	yes	5.27
E-CURD-10	no	857.99
E-MTAB-7037	no	399.80
E-MTAB-6678	no	3.32
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PITX2

miRNA regulators (miRDB)

113 targeting RSU1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-8067	99.86	69.59	2260

Literature-anchored findings (GeneRIF, showing 20)

• alternative splicing of exon 8 of the RSU-1 RNA to produce the exon-deleted form constitutes a mechanism for reduction or loss of functional Rsu-1. The exon-deleted form was not found in normal tissue. (PMID:12510772)
• Rsu-1 links the Ras pathway with the IPP (integrin-linked kinase {ILK}, PINCH-1/LIMS1, parvin) complex and the perturbations of cell attachment-dependent signaling that occur in the malignant process (PMID:18436335)
• Rsu1 is required for EGF-induced activation of the p38 map kinase signaling (PMID:25482629)
• Upregulation of RSU1 is associated with metastatic breast cancer. (PMID:25647720)
• results showed that RSU-1 expression is elevated in HepG2 cells both at the mRNA and protein level (PMID:25750304)
• integrin/Rsu1/Rac1/actin signaling has a conserved role in modulating reward-related phenotypes, including ethanol consumption, across phyla (PMID:26170296)
• our results indicate the important role of RSU-1 in BC metastasis and set the foundations for its validation as potential BC metastasis marker. (PMID:28423706)
• Ras suppressor protein 1 was confirmed to be directly targeted by miR-409-5p in breast cancer cells. Small interfering RNA-mediated Ras suppressor protein 1 inhibition reversely promoted cancer proliferation and migration in miR-409-5p-downregualted breast cancer cells. MiR-409-5p is downregulated in breast cancer and its inhibition has anti-cancer effect on breast cancer development both in vitro and in vivo. (PMID:28459205)
• This gene encodes a protein that is involved in the Ras signal transduction pathway, growth inhibition, and nerve-growth factor induced differentiation processes. (PMID:30621163)
• Ras suppressor-1 (RSU-1) promotes cell invasion in aggressive glioma cells and inhibits it in non-aggressive cells through STAT6 phospho-regulation. (PMID:31123330)
• Depletion of Ras Suppressor-1 (RSU-1) promotes cell invasion of breast cancer cells through a compensatory upregulation of a truncated isoform. (PMID:31296919)
• Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. (PMID:32592097)
• MicroRNA-Dependent Targeting of RSU1 and the IPP Adhesion Complex Regulates the PTEN/PI3K/AKT Signaling Pathway in Breast Cancer Cell Lines. (PMID:32751711)
• Complex structures of Rsu1 and PINCH1 reveal a regulatory mechanism of the ILK/PINCH/Parvin complex for F-actin dynamics. (PMID:33587032)
• RSU-1 interaction with prohibitin-2 links cell-extracellular matrix detachment to downregulation of ERK signaling. (PMID:33853759)
• Molecular basis for Ras suppressor-1 binding to PINCH-1 in focal adhesion assembly. (PMID:33891945)
• Focal adhesion proteins in hepatocellular carcinoma: RSU1 a novel tumour suppressor with prognostic significance. (PMID:35642986)
• Ras suppressor-1 (RSU1) exerts a tumor suppressive role with prognostic significance in lung adenocarcinoma. (PMID:35729367)
• Ras suppressor 1 long form (RSU1L) silencing promotes apoptosis in invasive breast cancer cells. (PMID:36375714)
• CircRSU1 alleviates LPS-induced human pulmonary microvascular endothelial cell injury by targeting miR-1224-5p/ITGA5 axis. (PMID:38312030)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rsu1	ENSDARG00000102885
mus_musculus	Rsu1	ENSMUSG00000026727
rattus_norvegicus	Rsu1	ENSRNOG00000017595
drosophila_melanogaster	ics	FBGN0028546
caenorhabditis_elegans		WBGENE00007924

Protein

Protein identifiers

Ras suppressor protein 1 — Q15404 (reviewed: Q15404)

All UniProt accessions (1): Q15404

UniProt curated annotations — full annotation on UniProt →

Function. Potentially plays a role in the Ras signal transduction pathway. Capable of suppressing v-Ras transformation in vitro.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15404-1	1	yes
Q15404-2	2

RefSeq proteins (2): NP_036557, NP_689937 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050216	LRR_domain-containing	Family
IPR055414	LRR_R13L4/SHOC2-like	Domain

Pfam: PF13855, PF23598

UniProt features (39 total): helix 14, strand 10, repeat 7, region of interest 2, compositionally biased region 2, initiator methionine 1, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
7D2S	X-RAY DIFFRACTION	1.65
7LT8	X-RAY DIFFRACTION	1.76
7D2T	X-RAY DIFFRACTION	2.2
7LT9	X-RAY DIFFRACTION	3.05
7D2U	X-RAY DIFFRACTION	3.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15404-F1	94.98	0.93

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-446388	Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
R-HSA-1500931	Cell-Cell communication
R-HSA-446353	Cell-extracellular matrix interactions
R-HSA-446728	Cell junction organization

MSigDB gene sets: 199 (showing top): YANG_BREAST_CANCER_ESR1_LASER_DN, SRF_Q5_01, chr10p13, SRF_C, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_RAS_PROTEIN_SIGNAL_TRANSDUCTION, SCHLOSSER_SERUM_RESPONSE_DN, APPIERTO_RESPONSE_TO_FENRETINIDE_DN, SESTO_RESPONSE_TO_UV_C7, VANTVEER_BREAST_CANCER_ESR1_DN, ATGTCAC_MIR489, GOBP_CELL_SUBSTRATE_ADHESION, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_CELL_MATRIX_ADHESION, IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR

GO Biological Process (5): cell-matrix adhesion (GO:0007160), signal transduction (GO:0007165), Ras protein signal transduction (GO:0007265), positive regulation of cell-substrate adhesion (GO:0010811), positive regulation of GTPase activity (GO:0043547)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), focal adhesion (GO:0005925), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cell-extracellular matrix interactions	1
Cell junction organization	1
Cell-Cell communication	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-substrate adhesion	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
small GTPase-mediated signal transduction	1
regulation of cell-substrate adhesion	1
positive regulation of cell adhesion	1
GTPase activity	1
regulation of GTPase activity	1
positive regulation of hydrolase activity	1
binding	1
cytoplasm	1
cellular anatomical structure	1
cell-substrate junction	1
extracellular vesicle	1

Protein interactions and networks

STRING

1200 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RSU1	LIMS1	P48059	971
RSU1	PARVA	Q9NVD7	928
RSU1	ILK	P57043	896
RSU1	PARVB	Q9HBI1	881
RSU1	PARVG	Q9HBI0	866
RSU1	RSPH6A	Q9H0K4	757
RSU1	RSPH3	Q86UC2	713
RSU1	LIMS2	Q7Z4I7	608
RSU1	PXN	P49023	600
RSU1	TLN1	Q9Y490	592
RSU1	VCL	P18206	586
RSU1	TLN2	Q9Y4G6	571
RSU1	FLNB	O75369	522
RSU1	FLNA	P21333	518
RSU1	FLNC	Q14315	503

IntAct

44 interactions, top by confidence:

A	B	Type	Score
ILK	LIMS1	psi-mi:“MI:0914”(association)	0.960
LIMS1	ILK	psi-mi:“MI:0914”(association)	0.960
RSU1	LIMS1	psi-mi:“MI:0915”(physical association)	0.850
LIMS1	RSU1	psi-mi:“MI:0915”(physical association)	0.850
RSU1	LIMS1	psi-mi:“MI:0914”(association)	0.850
PARVG	LIMS1	psi-mi:“MI:0914”(association)	0.640
ILK	HAX1	psi-mi:“MI:0914”(association)	0.530
ILK	ILVBL	psi-mi:“MI:0914”(association)	0.530
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
RSU1	GSK3B	psi-mi:“MI:0915”(physical association)	0.370
RSU1	GCNT1	psi-mi:“MI:0915”(physical association)	0.370
ILK	ELOC	psi-mi:“MI:0914”(association)	0.350
	VWA8	psi-mi:“MI:0914”(association)	0.350
PSKH1	AIP	psi-mi:“MI:0914”(association)	0.350
MAPK3	HMMR	psi-mi:“MI:0914”(association)	0.350
SPDYE4	RPS10-NUDT3	psi-mi:“MI:0914”(association)	0.350
	SDCBP	psi-mi:“MI:0914”(association)	0.350
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
	HLA-C	psi-mi:“MI:0914”(association)	0.350
FKBP5	IFT56	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
RSU1	ICAM2	psi-mi:“MI:0914”(association)	0.350
PARVG	MTX2	psi-mi:“MI:0914”(association)	0.350
ILK	PGAM2	psi-mi:“MI:0914”(association)	0.350

BioGRID (103): RSU1 (Two-hybrid), RSU1 (Affinity Capture-MS), PARVA (Affinity Capture-MS), PARVB (Affinity Capture-MS), ILK (Affinity Capture-MS), LIMS1 (Affinity Capture-MS), RSU1 (Affinity Capture-MS), CBS (Co-fractionation), HNRNPA3 (Co-fractionation), ILK (Co-fractionation), LIMS1 (Co-fractionation), NDUFA8 (Co-fractionation), NTMT1 (Co-fractionation), PARVA (Co-fractionation), PFKP (Co-fractionation)

ESM2 similar proteins: A0A2R8QFQ6, A0A2R8RWN9, A6H779, B5DFK7, O35345, O60684, Q01730, Q15303, Q15404, Q17QS6, Q28D01, Q2HJ19, Q3ULA2, Q502M6, Q503E9, Q58DG6, Q5E9C0, Q5R3Z8, Q5R4Q7, Q5RBV0, Q5SP67, Q5SRY7, Q5XIJ5, Q5ZIN0, Q5ZJX1, Q61527, Q62956, Q67FW5, Q6DD70, Q6GL10, Q862Z2, Q8BH16, Q8C6G8, Q8N653, Q8N6D5, Q8VBX0, Q8VCV1, Q8VEG6, Q8WXK3, Q91854

Diamond homologs: Q01730, Q15404, Q5E9C0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3158 predictions. Top by Δscore:

Variant	Effect	Δscore
10:16593391:T:TA	donor_gain	1.0000
10:16593397:T:C	donor_gain	1.0000
10:16593492:AGAGG:A	acceptor_gain	1.0000
10:16593493:GAGG:G	acceptor_gain	1.0000
10:16593494:AGG:A	acceptor_gain	1.0000
10:16593494:AGGC:A	acceptor_loss	1.0000
10:16593495:GG:G	acceptor_gain	1.0000
10:16593495:GGC:G	acceptor_loss	1.0000
10:16593496:GCT:G	acceptor_loss	1.0000
10:16593497:C:CC	acceptor_gain	1.0000
10:16593497:C:G	acceptor_loss	1.0000
10:16593498:T:C	acceptor_loss	1.0000
10:16695015:CTACT:C	donor_loss	1.0000
10:16695016:TACTT:T	donor_loss	1.0000
10:16695017:ACT:A	donor_loss	1.0000
10:16695018:CT:C	donor_loss	1.0000
10:16695019:TT:T	donor_loss	1.0000
10:16695020:TACTA:T	donor_loss	1.0000
10:16695021:A:AC	donor_gain	1.0000
10:16695021:ACTAT:A	donor_loss	1.0000
10:16695022:C:CA	donor_gain	1.0000
10:16695022:CT:C	donor_gain	1.0000
10:16695022:CTA:C	donor_gain	1.0000
10:16695022:CTAT:C	donor_gain	1.0000
10:16695022:CTATT:C	donor_gain	1.0000
10:16695153:TTC:T	acceptor_gain	1.0000
10:16695154:TCCT:T	acceptor_loss	1.0000
10:16695156:C:A	acceptor_loss	1.0000
10:16695156:C:CC	acceptor_gain	1.0000
10:16752533:CCTTA:C	donor_loss	1.0000

AlphaMissense

1838 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:16695102:A:G	W218R	1.000
10:16695102:A:T	W218R	1.000
10:16695106:A:C	N216K	1.000
10:16695106:A:T	N216K	1.000
10:16752567:G:C	N190K	1.000
10:16752567:G:T	N190K	1.000
10:16752583:A:G	L185P	1.000
10:16752636:G:C	N167K	1.000
10:16752636:G:T	N167K	1.000
10:16752652:A:G	L162P	1.000
10:16752925:A:C	L159W	1.000
10:16752969:G:C	N144K	1.000
10:16752969:G:T	N144K	1.000
10:16752985:A:G	L139P	1.000
10:16754914:G:C	N119K	1.000
10:16754914:G:T	N119K	1.000
10:16754930:A:G	L114P	1.000
10:16754939:A:T	L111H	1.000
10:16754983:G:C	N96K	1.000
10:16754983:G:T	N96K	1.000
10:16764399:A:G	L91P	1.000
10:16764452:G:C	N73K	1.000
10:16764452:G:T	N73K	1.000
10:16593494:A:G	L245P	0.999
10:16695030:A:C	Y242D	0.999
10:16695030:A:G	Y242H	0.999
10:16695039:A:G	S239P	0.999
10:16695056:A:T	V233D	0.999
10:16695089:A:T	I222N	0.999
10:16695100:C:A	W218C	0.999

dbSNP variants (sampled 300 via entrez): RS1000028311 (10:16661236 G>T), RS1000033446 (10:16788174 T>C), RS1000039935 (10:16662988 A>C), RS1000053800 (10:16784866 T>C), RS1000060898 (10:16783304 T>C), RS1000064030 (10:16792460 C>A,G), RS1000078055 (10:16675930 T>G), RS1000080547 (10:16687659 A>G), RS1000088114 (10:16693593 G>A,T), RS1000106565 (10:16621194 G>T), RS1000126604 (10:16723046 A>G), RS1000127618 (10:16697464 A>G,T), RS1000138533 (10:16656714 C>G,T), RS1000139373 (10:16679825 C>A,T), RS1000174557 (10:16712839 T>C)

Disease associations

OMIM: gene MIM:179555 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000988_1	Urinary albumin excretion	1.000000e-11
GCST001762_535	Obesity-related traits	6.000000e-06
GCST001762_55	Obesity-related traits	4.000000e-07
GCST001762_68	Obesity-related traits	5.000000e-06
GCST001762_850	Obesity-related traits	8.000000e-06
GCST001762_893	Obesity-related traits	2.000000e-06
GCST003254_2	Urinary albumin-to-creatinine ratio in non-diabetics	4.000000e-06
GCST004656_1	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.	9.000000e-06
GCST005173_31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	8.000000e-06
GCST005231_33	Major depressive disorder	3.000000e-06
GCST006633_22	Initial alcohol sensitivity	3.000000e-06
GCST009378_26	Bone mineral content	6.000000e-07
GCST009391_1969	Metabolite levels	5.000000e-06
GCST010105_21	Nicotine dependence symptom count	5.000000e-06
GCST010105_98	Nicotine dependence symptom count	2.000000e-06
GCST010988_437	Adult body size	3.000000e-12
GCST90002401_204	Platelet distribution width	8.000000e-54
GCST90002402_109	Platelet count	8.000000e-10

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0004285	albuminuria
EFO:0004887	maximal oxygen uptake measurement
EFO:0004908	testosterone measurement
EFO:0007778	urinary albumin to creatinine ratio
EFO:0008204	left ventricular diastolic function measurement
EFO:0004723	coronary artery calcification
EFO:0007621	bone mineral content measurement
EFO:0010541	trimethylamine-N-oxide measurement
EFO:0009262	nicotine dependence symptom count
EFO:0007984	platelet component distribution width
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067230 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
bisphenol A	affects cotreatment, affects methylation, increases expression	4
Smoke	decreases expression, increases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression, decreases expression	1
beta-lapachone	decreases expression	1
arsenite	increases methylation	1
sodium arsenite	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
calfactant	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Bortezomib	increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, affects methylation	1
Cisplatin	affects cotreatment, increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Folic Acid	decreases expression	1
Furaldehyde	affects cotreatment, affects localization, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652972	Binding	Binding affinity to human RSU1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.